Open AccessInfluence of paroxetine and hydroxyzine hydrochloride therapy on anxiety-depressive disorders and platelet serotonin level in CAD patients
Author(s) -
С. Н. Козлова,
А. В. Голубев,
Юлия Сергеевна Крылова,
Е. В. Шляхто,
Н. Г. Незнанов,
Надежда Степановна Кадышева
Publication year - 2012
Publication title -
arterialʹnaâ gipertenziâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.126
H-Index - 5
eISSN - 2411-8524
pISSN - 1607-419X
DOI - 10.18705/1607-419x-2012-18-6-554-559
Subject(s) - paroxetine , hydroxyzine , anxiety , medicine , depression (economics) , serotonin , coronary artery disease , psychology , anesthesia , psychiatry , antidepressant , receptor , macroeconomics , economics
Objective. Open, comparative, randomized study of efficiency, safety and assessment of influence of paroxetine and hydroxyzine hydrochloride therapy on platelet serotonin level in patients with coronary artery disease (CAD) and comorbid anxiety-depressive disorders were examined. Design and methods. We included 40 patients with chronic CAD and comorbid anxiety-depressive disorders, confirmed according to ICD-10. Patients with score more than 18 by Hamilton’s scale of anxiety and depression were enrolled. Results. We observed significant decrease Hamilton’s scale scores after 4 weeks of treatment, and after 8 weeks of treatment the reduction reached 50 %. Side effects were registered in both groups and quickly passed after the drug withdrawal. Platelet serotonin level decreased significant during paroxetine therapy. Conclusion. Treatment by paroxetine and hydroxyzine hydrochloride was associated with high anti-anxiety and anti-depressive activity. Use of paroxetine was associated with significant reduction of platelet serotonin level.